Abba Hushi Avenue
About Check-CapCheck-Cap is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening.
The Check-Cap device requires no bowel preparation or invasive procedures, and is designed to detect clinically significant polyps with a high degree of sensitivity. Check-Cap's advanced technology has been proven in animals, and is designed to offer several advantages compared to current screening procedures.
Founded in early 2005, Check-Cap recruited a team of world-class experts in physics, software engineering, electronics, mechanics and physiology, who have been developing a multi-disciplinary imaging solution for imaging and screening of the colon. The system includes a capsule, a receiver, proprietary imaging software and an associated database for web based access and analysis.
For more information, visit www.check-cap.com and follow us on www://twitter.com/checkcap_.
Founder: Yoav Kimchy
CEO: Bill Densel
CTO: Yoav Kimchy
CFO: Lior Torem
X-ray Radar Device
Tweets by Check-Cap
31 articles with Check-Cap
7/11/2019Companies from across Europe, Asia and around the globe share pipeline and business updates.
Check-Cap Ltd., announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.
6/7/2019Pharma and biotech companies strengthen their executive and leadership teams with new appointments.
Mr. Belkar Brings More Than 20 Years of Global Medical Device Experience, Including at Medtronic and Mazor Robotics
Check-Cap to Present Data at Digestive Disease Week® Demonstrating Substantial Improvement in Precancerous Polyp Detection
Check-Cap Ltd. announced that it will present data at Digestive Disease Week 2019, to be held on May 18-21, 2019 in San Diego, California.
Mayo Clinic joins New York University in pilot study of C-Scan® in the U.S.
Initiates U.S. pilot study of C-Scan® at NYU School of Medicine and Mayo Clinic
Check-Cap Ltd. today announced the initiation of its U.S. pilot study of the C-Scan® system, following Institutional Review Board approval and full Investigational Device Exemption application approval by the U.S. Food and Drug Administration.
Check-Cap is a clinical stage medical diagnostics company advancing the development of C-Scan®
3/22/2019Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
Check-Cap Ltd., announced it has received Institutional Review Board approval from New York University School of Medicine to initiate a U.S. pilot study of the C-Scan® system.
Check-Cap Ltd. today announced that it has entered into definitive agreements with institutional investors for the purchase of 2,906,376 units, at a purchase price of $2.58 per unit, in a registered direct offering.
Study to begin upon review and approval of Institutional Review Board (IRB)
Announced Interim Results from Post-CE Approval Study of C-Scan®
If Approved, U.S. Pilot Study Anticipated to Commence in 4Q 2018
Check-Cap Receives Approval From the Israeli Ministry of Health to Initiate Commercial Sales in Israel of its C-Scan® System
Check-Cap Ltd. today announced it has received approval from the Israeli Ministry of Health, the Medical Device Division (known as "AMAR"), to initiate commercial sales in Israel of the C-Scan system that received CE Mark approval in January 2018.
Check-Cap Announces Promising Interim Results from its Ongoing Post-CE Approval Study of C-Scan® System Version 3
Management to present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference on Wednesday, September 5 at 3:00pm ET
Check-Cap Ltd. announced financial results for the second quarter and six months ended June 30, 2018.
Check-Cap Ltd. a clinical stage medical diagnostics company engaged in the development of C-Scan®, today announced that the results of its multicenter clinical study that examined C-Scan safety and efficacy (compared to FIT and colonoscopy) for polyp detection confirmed by ensuing colonoscopy.
Check-Cap Ltd. announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") that it has regained compliance with Nasdaq Listing Rule 5550(a)(2).